Sebastien Beauzile from Laurelton, Long Island, has become the first person in New York State to be cured of sickle cell ...

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

The approval of Vertex and partner CRISPR Therapeutics CRSP one-shot gene therapy Casgevy for two blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), has ...

By Deena Beasley (Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Gene therapy, which promises a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

He’s got new blood. A Long Island hospital said it administered life-changing Lyfgenia gene therapy treatment and successfully wiped away sickle cell disease from a Laurelton man. Cohen Children ...

Vertex Pharmaceuticals Incorporated ... The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of ...

But in December, Beauzile, 21, became the first person in New York State to be made symptom-free of sickle cell disease after undergoing Lyfgenia, a new type of gene therapy that uses stem cell ...